Person · 3 episodes
Andrew Huberman
Every Onpode episode on Andrew Huberman.
Episodes
Huberman: GLP-1 meds like Ozempic killed needle phobia, now peptides are boomingUS searches for 'peptide' jumped sixfold — from 201,000 monthly in April 2025 to 1.2 million by March 2026 — as Andrew Huberman publicly linked GLP-1 drug adoption to reduced needle phobia and a broader peptide injection boom. The mechanism is plausible but unproven, and the peptide gray market it amplifies has no FDA approval or safety monitoring.
Huberman just dropped a 30-minute Essentials episode on OCD neural circuits and why SSRIs fall shortIn OCD, compulsions provide real, neurochemically genuine anxiety relief — but that relief strengthens the obsession, not weakens it. The cortico-striatal-thalamic loop encodes compulsions as habits via the basal ganglia. SSRIs outperform placebo but can't cleanly target this circuit, and AI models predicting OCD from brain scans achieve only 0.653 AUROC overall.
Dr. Andrew Huberman weighs in on retatrutide as a muscle-sparing GLP-1 alternativeRetatrutide, Eli Lilly's triple GLP-1/GIP/glucagon agonist, produced 28.7% average body weight loss and a 75.8% reduction in knee pain in the Phase 3 TRIUMPH-4 trial — roughly double semaglutide's benchmark. Andrew Huberman called it a 'trillion-dollar drug' on the Goop Podcast, but retatrutide remains FDA-unapproved, with seven Phase 3 trials still running.